Clinical Trial

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2021-01-08; most recent amendment 2026-05-26.
Status change: Recruiting → Active, Not Recruiting 2024-10-23
Status change: Not Yet Recruiting → Recruiting 2021-07-06
Trial Details
NCT Number NCT04704934
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca
Conditions Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment 490 participants
Start Date 2021-05-21
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-27